Drug Management of Prostate Cancer

Inbunden, Engelska, 2010

AvWilliam D. Figg,Cindy H. Chau,Eric J. Small

2 829 kr

Beställningsvara. Skickas inom 10-15 vardagar. Fri frakt för medlemmar vid köp för minst 249 kr.

Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges’ report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.

Produktinformation

Utgivningsdatum2010-09-17
Mått190 x 260 x 29 mm
Vikt1 147 g
FormatInbunden
SpråkEngelska
Antal sidor430
Upplaga2010
FörlagHumana Press Inc.
ISBN9781603278317

Tillhör följande kategorier

Onkologi inom Medicin
Urologi inom Medicin

Cell Biology of Prostate Cancer and Molecular Targets.- Cell Biology of Prostate Cancer and Molecular Targets.- Hormone Therapy.- Luteinizing Hormone-Releasing Hormone and Its Agonistic, Antagonistic, and Targeted Cytotoxic Analogs in Prostate Cancer.- Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer.- Androgens and Prostate Cancer.- Androgen Receptor Biology in Prostate Cancer.- Androgen Receptor Antagonists.- 5-Alpha Reductase Inhibitors in Prostate Cancer.- Adrenal Androgen Synthesis Inhibitor Therapies in Castration-Resistant Prostate Cancer.- Androgen Deprivation Therapy.- Pharmacogenetics of the Androgen Metabolic Pathway.- Chemotherapy.- Mitoxantrone.- Docetaxel.- Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer.- Platinum Agents in Prostate Cancer.- Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer.- Microtubule Targeting Agents.- Angiogenesis.- Principles of Antiangiogenic Therapy.- Bevacizumab in Advanced Prostate Cancer.- Thalidomide and Analogs.- Investigational Angiogenesis Inhibitors.- Pharmacogenetics of Angiogenesis.- Bone Metastasis.- Pathophysiology of Prostate Cancer Bone Metastasis.- Radiopharmaceuticals.- Bisphosphonates for Prevention and Treatment of Bone Metastases.- Endothelin Receptors as Therapeutic Targets in Castration-Resistant Prostate Cancer.- Calcitriol and Vitamin D Analogs.- Immunotherapy.- Cancer Immunology, Immunotherapeutics, and Vaccine Approaches.- Sipuleucel-T: Autologous Cellular Immunotherapy for Metastatic Castration-Resistant Prostate Cancer.- GM-CSF Gene-Transduced Prostate Cancer Vaccines: GVAX.- CTLA-4 Blockade for Prostate Cancer Treatment.- Prevention.- Prostate Cancer Chemoprevention Strategies.- Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk.- Inflammation as a Target in Prostate Cancer.- Drug Development.- Challenges for the Development of New Agents in Prostate Cancer.- FDA Approval ofProstate Cancer Treatments.- Applications of Proteomics in Prostate Cancer.- Erratum to: Docetaxel.- Erratum to: Docetaxel.

From the reviews: "For medical oncologists, trainees, researchers, and those in the pharmaceutical industry, Figg ... offer a comprehensive and concise summary of the pharmacological treatments for prostate cancer, both current standard and investigative options. The 36 chapters ... focus on a multidisciplinary care approach and cover hormone therapy, chemotherapy, angiogenesis, therapy for bones metastases, immunotherapy, chemoprevention, and drug development. Cell biology and molecular targets are also discussed." (SciTech Book News, December, 2010) "The 36 chapters in this book ... read as independent discussions of many of the most recent discoveries in the area of drug management of prostate cancer. ... suitable for medical students, physicians in training, physicians (especially medical oncologists), scientists, translational researchers, and members of the pharmaceutical industry. ... An important aspect of this book is that the data represents updated, state-of-the-art information, making it valuable for daily reference. ... an excellent resource for readers interested in the management of advanced prostate cancer ... ." (Jianqing Lin, Doody's Review Service, December, 2010) "This treatise is an exhaustive description of the application of drug management of prostate cancer involving both standard care and investigational agents. ... this book will give the reader a detailed insight about the current knowledge from clinical trials into the drug treatment of prostate tumours. The urologists, medical oncologist and others involved in the treatment of the prostate cancer will find in this work a complete review of where we are now." (M. Hornak, Neoplasma, March, 2011) "This textbook by W.D. Figg and co-authors ... makes an exhaustive overview of present and future medical therapies of prostate cancer. ... This book provides the reader with comprehensive information about pharmacological treatments of prostate cancer. All chapters are concise and most of them are well-illustrated. We recommend this textbook to urologists, oncologists who are involved in prostate cancer management, and to all physicians and students who want to update their knowledge in prostate cancer management." (European Urology Today, April/May, 2011)